WEHR, Claudia, Teemu KIVIOJA, Christian SCHMITT, Berne FERRY, Torsten WITTE, Efrem EREN, Marcela VLKOVA, Manuel HERNANDEZ, Drahomíra DEDKOVA, Philip R. BOS, Gonke POERKSEN, Horst VON BEMUTH, Ulrich BAUMANN, Sigune GOLDACKER, Sylvia GUTENBERGER, Michael SCHLESIER, Florence BERGERON-VAN DER CRUYSSEN, Magali LE GARFF, Patrice DEBRÉ, Roland JACOBS, John JONES, Elizabeth BATERMAN, Jiří LITZMAN, P. Martin VAN HAGEN, Alessandro PLEBANI, Reinhold E. SCHMIDT, Vojtěch THON, Isabella QUINTI, Teresa ESPANOL, A. David WEBSTER, Helen CHAPEL, Mauno VIHINEN, Eric OKSENHENDLER, Hans Hartmut PETER and Klaus WARNATZ. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008, vol. 111, No 1, p. 77-85. ISSN 0006-4971.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name The EUROclass trial: defining subgroups in common variable immunodeficiency.
Name in Czech EUROclasss: definice podskupin pacientů s běžným variabilním imunodeficitem
Authors WEHR, Claudia, Teemu KIVIOJA, Christian SCHMITT, Berne FERRY, Torsten WITTE, Efrem EREN, Marcela VLKOVA, Manuel HERNANDEZ, Drahomíra DEDKOVA, Philip R. BOS, Gonke POERKSEN, Horst VON BEMUTH, Ulrich BAUMANN, Sigune GOLDACKER, Sylvia GUTENBERGER, Michael SCHLESIER, Florence BERGERON-VAN DER CRUYSSEN, Magali LE GARFF, Patrice DEBRÉ, Roland JACOBS, John JONES, Elizabeth BATERMAN, Jiří LITZMAN, P. Martin VAN HAGEN, Alessandro PLEBANI, Reinhold E. SCHMIDT, Vojtěch THON, Isabella QUINTI, Teresa ESPANOL, A. David WEBSTER, Helen CHAPEL, Mauno VIHINEN, Eric OKSENHENDLER, Hans Hartmut PETER and Klaus WARNATZ.
Edition Blood, 2008, 0006-4971.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30102 Immunology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 10.432
Organization unit Faculty of Medicine
UT WoS 000252002000016
Keywords (in Czech) běžná variabilní imunodeficience; FACS; klasifikace
Keywords in English common variable immunodefciency; B-lymphocytes; classification
Tags B-lymphocytes, CLASSIFICATION, common variable immunodefciency
Tags International impact, Reviewed
Changed by Changed by: prof. MUDr. Jiří Litzman, CSc., učo 403. Changed: 2/4/2010 08:02.
Abstract
The heterogeneity of common variable immunodeficiency (CVID) calls for a classification addressing pathogenic mechanisms as well as clinical relevance. This European multicenter trial was initiated to develop a consensus of 2 existing classification schemes based on flowcytometric B-cell phenotyping and the clinical course. The clinical evaluation of 303 patients with the established diagnosis of CVID demonstrated a significant coincidence of granulomatous disease, autoimmune cytopenia, and splenomegaly. Phenotyping of B-cell subpopulations confirmed a severe reduction of switched memory B cells in most of the patients that was associated with a higher risk for splenomegaly and granulomatous disease. An expansion of CD21(low) B cells marked patients with splenomegaly. Lymphadenopathy was significantly linked with transitional B-cell expansion. Based on these findings and pathogenic consideration of B-cell differentiation, we suggest an improved classification for CVID (EUROclass), separating patients with nearly absent B cells (less than 1%), severely reduced switched memory B cells (less than 2%), and expansion of transitional (more than 9%) or CD21(low) B cells (more than 10%). Whereas the first group contains all patients with severe defects of early B-cell differentiation, severely reduced switched memory B cells indicate a defective germinal center development as found in inducible constimulator (ICOS) or CD40L deficiency. The underlying defects of expanded transitional or CD21(low) B cells remain to be elucidated.
Abstract (in Czech)
Byla získána data od 303 pacientů s běžným variabilním imunodeficitem ( CVID). Na základě počtu buněk definovaných B-lymfocytárních subpopulací u jednotlivých pacientů bylo navrženo nové klasifikační schéma CVID.
Links
NR9035, research and development projectName: Specifická protilátková odpověď u pacientů s poruchami imunity
PrintDisplayed: 5/5/2024 10:41